This site is intended for healthcare professionals
Responding to unmet needs for metastatic castration-resistant prostate cancer
mCRPC in focus

mCRPC update: Best practice and new insights

Last updated:2nd May 2024
Published:2nd May 2024

Live, virtual 60-minute roundtable

19 June 2024 – 15:00–16:00 UTC

Attend this roundtable to hear the latest on best practice mCRPC management and put questions to the expert faculty

  • Approaches for non-continuous androgen-deprivation monotherapy (ADT) for mCRPC, such as intermittent ADT
  • Non-androgen-deprivation approaches for mCRPC, with a focus on bone resorptive agents
  • Systemic therapy for mCRPC, timing and sequencing
  • Best-practice mCRPC symptom management, including radiation therapy and pain management

Professors Neeraj Agarwal, Axel Merseburger, Karim Fizazi, and Bárbara Vieira Lima Aguiar Melão will explore these topics, consider the potential impact of data presented at the 2024 ASCO Genitourinary Cancers Symposium and 2024 ASCO Annual Meeting, and highlight the in-progress trials to watch out for.

Register

Not sure you can attend live? Register anyway and we’ll let you know when it becomes available to watch on demand.

Agenda

mCRPC update: Best practice and new insights
19 June 2024 – 15:00–16:00 UTC
Chair: Neeraj Agarwal
Welcome and introductions Neeraj Agarwal
Androgen-deprivation therapy sparing for managing mCRPC Axel Merseburger
Non-androgen-deprivation therapy approaches for managing mCRPC Karim Fizazi
A case-based approach to treatment sequencing for mCRPC Bárbara Vieira Lima Aguiar Melão
Best practice symptom management for mCRPC Neeraj Agarwal
Live Q&A All faculty
Takeaways and close Neeraj Agarwal

Register now for the mCRPC update: Best practice and new insights roundtable

Thank you for signing up for the mCRPC update: Best practice and new insights roundtable

Event live link 

Click the icon below to add the live webinar to your preferred calendar to make sure you do not miss out.

Add event to calendar

AppleGoogleOffice 365OutlookOutlook.comYahoo

Webinar tips

  • Internet Explorer and older versions of Microsoft EDGE are not supported
  • If you are viewing via a mobile device or tablet – ‘Join this webinar’ – choose ‘with browser’
  • If you are removed from the webinar at any time, refresh the browser page and add your name and email address again to re-access
  • In the webinar room, you can dock the video pod into the top right-hand corner of the screen by clicking on the 2 squares symbol
  • Please wait until the meeting has ended to be directed to a short feedback form
Optional: I confirm that I am happy to receive further information about this roundtable and relevant Medthority updates by email.

Faculty

Professor Neeraj Agarwal

Professor Agarwal is a Professor of Medicine and a Presidential-Endowed Chair of cancer research at the Huntsman Cancer Institute (HCI), University of Utah, USA, where he also serves as Senior Director for Clinical Research. He also directs the HCI's Genitourinary Oncology Program and the Center of Investigational Therapeutics.

Disclosures: Consultancy to Astellas, AstraZeneca, AVEO, Bayer, Bristol Myers Squibb, Calithera, Clovis, Eisai, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Lilly, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, and Seagen.

Research funding to institution (lifetime): Arvinas, Astellas, AstraZeneca, Bavarian Nordic, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, CRISPR Therapeutics, Eisai, EMD Serono, Exelixis, Genentech, Gilead, GSK, Immunomedics, Janssen, Lava, Lilly, Medivation, Merck, Nektar, Neoleukin, NewLink Genetics, Novartis, ORIC, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seagen, Takeda, Telix, and Tracon.

Professor Axel Merseburger

Professor Merseburger is Professor of Urology and chair of the Department of Urology at University Hospital Schleswig-Holstein, Germany. He is chair for the European Scholarship Program and a board member of the European Association of Urology. He is Editor-in-Chief of the European Journal of Haematology and Oncology and Aktuelle Urologie.

Disclosures: Lectures/speaker/honoraria: Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ferring, Ipsen, Janssen, Merck Serono, MSD, Novartis, Pfizer, Recordati, Roche, Takeda, and Teva. Consultancy: Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, EUSAPharm, Ferring, Ipsen, Janssen, Merck Serono, MSD, Novartis, Pfizer, Recordati, Roche, Takeda, and Teva. Research and clinical trials: Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, EUSAPharm, Ipsen, Janssen, Merck Serono, MSD, Novartis, Pfizer, Recordati, Roche, Takeda, and Teva.

Professor Karim Fizazi

Professor Fizazi is a medical oncologist at Institut Gustave Roussy and Professor in Oncology at the Université Paris-Saclay, France. He is President of the French Groupe d’Etude des Tumeurs Genito-Urinaires (GETUG). Professor Fizazi is Associate Editor of the European Journal of Cancer.

Disclosures: Participation in advisory boards and talks for Amgen, Astellas, AstraZeneca, Bayer, Clovis, Daiichi Sankyo, Janssen, MSD, Novartis/AAA, Pfizer, and Sanofi. Honoraria go to Gustave Roussy. Participation in advisory boards with personal honorarium for Arvinas, CureVac, and Orion.

Professor Bárbara Vieira Lima Aguiar Melão

Professor Melão is Director of Oncology at the Adventist Hospital of Manaus, Brazil, and a member of the Brazilian Society of Urology (SBU). She is a PhD student at the Faculty of Medicine at the University of São Paulo.

Disclosures: Clinical trials: Janssen. Speaker: Aspen, Janssen. 

Welcome: